Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

Jeffrey A. Switzer, David C. Hess, Adviye Ergul, Jennifer L. Waller, Livia S. MacHado, Vera Portik-Dobos, L. Creed Pettigrew, Wayne Clark, Susan C. Fagan

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P

Original languageEnglish (US)
Pages (from-to)2633-2635
Number of pages3
JournalStroke
Volume42
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Minocycline
Matrix Metalloproteinase 9
Stroke
Plasminogen Activators
Hemorrhage

Keywords

  • acute stroke
  • inflammation
  • neuroprotection

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Switzer, J. A., Hess, D. C., Ergul, A., Waller, J. L., MacHado, L. S., Portik-Dobos, V., ... Fagan, S. C. (2011). Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke, 42(9), 2633-2635. https://doi.org/10.1161/STROKEAHA.111.618215

Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. / Switzer, Jeffrey A.; Hess, David C.; Ergul, Adviye; Waller, Jennifer L.; MacHado, Livia S.; Portik-Dobos, Vera; Pettigrew, L. Creed; Clark, Wayne; Fagan, Susan C.

In: Stroke, Vol. 42, No. 9, 09.2011, p. 2633-2635.

Research output: Contribution to journalArticle

Switzer, JA, Hess, DC, Ergul, A, Waller, JL, MacHado, LS, Portik-Dobos, V, Pettigrew, LC, Clark, W & Fagan, SC 2011, 'Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke', Stroke, vol. 42, no. 9, pp. 2633-2635. https://doi.org/10.1161/STROKEAHA.111.618215
Switzer JA, Hess DC, Ergul A, Waller JL, MacHado LS, Portik-Dobos V et al. Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. Stroke. 2011 Sep;42(9):2633-2635. https://doi.org/10.1161/STROKEAHA.111.618215
Switzer, Jeffrey A. ; Hess, David C. ; Ergul, Adviye ; Waller, Jennifer L. ; MacHado, Livia S. ; Portik-Dobos, Vera ; Pettigrew, L. Creed ; Clark, Wayne ; Fagan, Susan C. / Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke. In: Stroke. 2011 ; Vol. 42, No. 9. pp. 2633-2635.
@article{b3a8526c77fa48dda5272a6adfbeef95,
title = "Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke",
abstract = "Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P",
keywords = "acute stroke, inflammation, neuroprotection",
author = "Switzer, {Jeffrey A.} and Hess, {David C.} and Adviye Ergul and Waller, {Jennifer L.} and MacHado, {Livia S.} and Vera Portik-Dobos and Pettigrew, {L. Creed} and Wayne Clark and Fagan, {Susan C.}",
year = "2011",
month = "9",
doi = "10.1161/STROKEAHA.111.618215",
language = "English (US)",
volume = "42",
pages = "2633--2635",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Matrix metalloproteinase-9 in an exploratory trial of intravenous minocycline for acute ischemic stroke

AU - Switzer, Jeffrey A.

AU - Hess, David C.

AU - Ergul, Adviye

AU - Waller, Jennifer L.

AU - MacHado, Livia S.

AU - Portik-Dobos, Vera

AU - Pettigrew, L. Creed

AU - Clark, Wayne

AU - Fagan, Susan C.

PY - 2011/9

Y1 - 2011/9

N2 - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P

AB - Background and Purpose-Plasma matrix metalloproteinase-9 levels predict posttissue plasminogen activator (tPA) hemorrhage. Methods-The authors investigated the effect of minocycline on plasma matrix metalloproteinase-9 in acute ischemic stroke in the Minocycline to Improve Neurological Outcome in Stroke (MINOS) trial and a comparison group. Results-Matrix metalloproteinase-9 level decreased at 72 hours compared with baseline in MINOS (tPA, P=0.0022; non-tPA, P=0.0066) and was lower than in the non-MINOS comparison group at 24 hours (tPA, P

KW - acute stroke

KW - inflammation

KW - neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=80052415005&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052415005&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.111.618215

DO - 10.1161/STROKEAHA.111.618215

M3 - Article

VL - 42

SP - 2633

EP - 2635

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 9

ER -